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End-stage liver disease is responsible for 30,000 deaths per year in the United States
alone, and it is continuing to increase every year. With liver transplantation the only
curative treatment currently available, new therapies are in great demand. Mesenchy-
mal stem cells (MSC) offer an opportunity to both treat liver inflammatory damage, as
well as reverse some of the changes that occur following chronic liver injury. With the
ability to regulate both the innate and adaptive immune system, as well as both inhibit
and promote apoptosis of effector inflammatory cells, there are numerous therapeutic
opportunities for MSC in acute and chronic liver disease. This article critically
appraises the potential therapeutic roles of MSC in liver disease, as well as the barriers
to their adoption into clinical practice.
liver disease; mesenchymal stem cell; mesenchymal stromal cell
IN THE UNITED STATES (US) there are 30,000 deaths each year
due to chronic liver disease, which is increasing at a rate of 3
percent per year (67). Currently, the only curative treatment for
end stage liver disease is transplantation, but there are over
15,000 patients on the waiting list for a liver transplant oper-
ation in the US, and 50% of these patients will never receive
a transplant (103a). In the United Kingdom (UK) the problem
is similar with 2% of all deaths being due to liver disease, and
while all other leading causes of death are decreasing, those
from end-stage liver disease have increased by 20% (69, 113).
Notably, liver disease is the leading cause of premature death
in the UK, leading to the loss of a greater number of life years
than many of the other causes. Clearly, novel therapeutic
options are needed to reduce the global impact of liver dis-
eases; mesenchymal stem cells (MSC) are one potential ther-
apy that offer great promise.
MSC are multipotent, self-renewing cells of mesodermal
origin that have the potential to differentiate down chondro-
cytic, osteocytic, and adipocytic lineages among many others
(78). MSC exist in a number of tissues, albeit in low numbers
(87), and have traditionally been isolated because of their
ability to adhere to tissue culture plastic and proliferate (28).
This review will cover the possible roles of MSC in liver
disease along with their potential pitfalls.
Evolution of a Bone Marrow Derived Stem Cell
The history of MSC and the development of hypotheses
regarding their existence date back over 100 years ago; indeed,
a description of bone marrow stroma creating an environment
in which hematopoietic precursors were able to differentiate
was first suggested as far back as 1908 by Maximov (27, 61).
Experiments in the 1960s by Tavassoli confirmed the osteo-
genic potential of bone marrow, but limitations with these
experiments meant it was not possible to identify which cel-
lular constituents within the bone marrow were responsible
(98). Further work by Friedenstein demonstrated that a rare
population of bone marrow cells with fibroblastic properties
were responsible, and the term colony-forming unit fibroblast
was used to describe them (99). These cells have subsequently
been shown to be multipotent (71), but their complex interplay
with hematopoietic stem cells has only recently been demon-
strated (62). The term MSC was not used until 1991 when it
was introduced by Caplan (16), and the idea of a stem cell
niche within the bone marrow was further developed by the
discovery of a rare, self-renewing population of cells (87),
leading to an ongoing debate regarding the correct criteria with
which to judge MSC. This is due to their mixture of stem- and
stromal cell-like properties, although the ability to self-renew
and tri-lineage differentiation potential (osteogenic, chondro-
genic, and adipogenic) appear in most definitions (13, 22).
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The definition of MSC in humans has focused on their
adherence to tissue culture plastic, multipotency, and expres-
sion profile of specific cell surface antigens (Table 1). As
regard the latter, a population of putative human MSC should
be greater than 95% positive for positive antigens and contain
less than 2% positivity for negative antigens (22, 39). In mice
however, CD105, CD90, and VCAM-1 have been identified as
relevant markers for MSC purity (Table 1), although successful
isolation of MSC from murine bone marrow has proven chal-
lenging (19, 74), leading to the isolation of markedly hetero-
geneous cell populations and potentially inconsistent results in
preclinical studies. Prospective isolation of MSC subpopula-
tions using cell-sorting techniques has been demonstrated in
both mice and humans. Highly purified mouse MSC obtained
from bone marrow by sorting on PDGFR and Sca-1 expres-
sion (with depletion of cells expressing Ter119 and CD45)
demonstrate tri-lineage differentiation and self-renewal
(66). In humans and mice, MSC can also be isolated on the
basis of their LNGFR (CD271), THY-1, and VCAM-1hi
(59) expression profile and again have been shown to
undergo tri-lineage differentiation and self-renewal. The
intermediate filament protein nestin has also been shown to
identify a population of perivascular MSC, which are able to
support the hematopoietic niche (62) and may also be used
as a marker for prospective isolation. Notably, the overlap
between PS and nestin-positive cells is not complete, with
the majority of nestin cells not expressing Sca-1, suggest-
ing some phenotypic differences (77).
MSC and immunomodulation. The number of studies look-
ing at MSC in the laboratory and clinical setting has increased
dramatically over the past decade due to their pleiotropic
actions in respect to regeneration and immunomodulation.
Their immunomodulatory properties apply to both the adaptive
and the innate immune systems and are seemingly mediated by
a combination of migration to inflamed tissues, as well as by
remote signaling (103, 109, 117).
Regarding the innate immune system MSC can inhibit the
maturation of dendritic cells (18, 44, 80), as well as decrease
their expression of MHC class 1, MHC class 2, and other
costimulatory molecules, thus reducing their antigen-present-
ing ability. It has been demonstrated in vitro that MSC can
inhibit the release of TNF- by dendritic cells via a PGE2-
dependent mechanism and also stimulate plasmacytoid den-
dritic cells to increase their production of IL-10 (1). This
reduction in inflammation is one of the mechanisms proposed
for the success of MSC in graft vs. host disease (55, 63). MSC
also have an inhibitory effect on natural killer (NK) cells likely
due to the release of soluble factors such as indoleamine-2,3-
dioxygenase (IDO), TGF-, PGE2, and IL-10 (Table 2 and Fig.
1). This inhibitory effect has been shown to prevent activation
of NK cells by IL-2; however, once NK cells are activated, the
inhibitory effect of MSC is only partial, measured by reduc-
tions in IFN secretion by NK cells (95). MSC can be induced
to increase their production of myosin heavy chain class 1 and
2 by activation using IFN, which has been shown to protect
MSC from NK-induced apoptosis (95).
Regarding the adaptive immune system, MSC are able to
inhibit T-cell proliferation and their activation; however, the
precise mechanisms by which this is achieved are unclear.
Early cell cycle arrest of T cells may have a role in their
suppressive action, and MSC have been shown to inhibit cyclin
D2 and upregulate p27Kip1, and although the mechanism is
not clear, this process is independent of MHC expression (33).
The suppressive activity of MSC is not however, limited to a
specific subset of T cells and has also been shown to occur
during CD40L and IL-4 stimulation of B cells, which likely
reflects the role of cyclin D2 in driving B-cell proliferation (82,
118). Notably, an inflammatory environment is required for
MSC to exert their immunosuppressive effect, as otherwise,
MSC have been shown paradoxically to exert a proinflamma-
tory effect on T-cells (68).
As well as human and mouse MSC possessing phenotypi-
cally different expression profiles, there are also differences
between strains of mice and rats with respect to their mode of
immunomodulation, with BALBc mice predominantly secret-
ing inducible nitric oxide, as opposed to IDO (9, 35). Human
MSC have also been shown to favor IDO as their mechanism
of immunosuppression (26); thus, it is critical to choose the
correct strain of mice for MSC isolation when carrying out
studies with a translational objective.
MSC in Liver Disease
The role of MSC has been studied in a range of different
settings of liver disease, with widely varying actions reported,
ranging from reduction of oxidative stress, paracrine trophic
signals to hepatocytes, to suppression of immune responses
and reduction of liver fibrosis. The majority of the literature
regarding MSC usage in patients with liver disease is made up
of either observational studies or case series. Table 3 summa-
rizes some of the key controlled trials carried out in this area.
Acute liver failure/acute on chronic liver failure. The rapid
onset of liver failure in patients without preexisting liver
disease is relatively uncommon but has considerable morbidity
and mortality, despite improvements in critical care provision
and liver transplant surgery (35a). Causes of acute liver failure
vary between the developing world, where viral infection is the
major cause, and the developed world, where drug-induced
liver injury is more common (12). Drug-induced liver injury is
responsible for 50% of cases of acute liver failure in the United
States (84) and Europe, where the main drug responsible is
acetaminophen (11).
In preclinical models of acute liver damage, such as from
carbon tetrachloride (CCl4) and concanavalin A, MSC have
been shown to reduce liver injury (46, 120), although the
mechanisms by which this is achieved are complex and not
fully understood. A reduction in proinflammatory cytokines, in
particular, TNF, IFN, and IL-4, may be responsible and in
Table 1. Presence and absence of surface markers required
for identification of human and mouse MSC
Positive Surface Antigens Negative Surface Antigens
Human Mouse Human Mouse
CD105 CD105 CD79 or CD19 CD45
CD90 (Thy1) CD90 CD45 Ter119
CD73 VCAM CD34
CD71 PDFR CD14 or CD11b
CD44 Sca1 HLA-DR
GD2 CD86
LNGFR (CD271) CD80
CD40
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some studies appears to be greater with repeated dosing of
MSC (17). In parallel with the reduction in inflammatory
cytokines, a reduction in hepatocyte apoptosis has also been
demonstrated using the TUNEL assay (48). Oxidative stress
plays a role in a number of liver injury models, including
CCL4-induced liver injury and hepatic ischemia reperfusion. In
CCL4-induced liver injury, MSC have been shown to reduce
oxidative stress, with parallel in vitro experiments, demonstrat-
ing an ability to act as a free radical scavenger, reducing the
amount of reactive oxygen species available (53). In acetamin-
ophen-induced liver injury, damage can be reduced by inhibi-
tion of JNK (34), which MSC have been demonstrated to
achieve along with reductions in hepatic JNK and TNF- and
maintenance of levels of hepatic glutathione (89).
MSC-conditioned media (MSC-CM) and MSC based extra-
corporeal membranes (MSC-EM) appear to be as effective, if
not more so, than MSC infusions alone in certain models. In
D-galactosamine-induced liver injury models, MSC-EM appear
to show a greater reduction in hepatocyte death and reversal of
fulminant hepatic failure, followed by MSC-CM with cellular
infusion showing the lowest effect (73). However, MSC-CM
contains over 50 cytokines, and it is yet to be elucidated what
combination of these is most effective in the treatment of liver
disease. The inability to, thus, identify a defined product is
likely to be problematic for regulators when trying to translate
this finding into clinical practice.
In the developing world, viral hepatitis is the most common
cause of acute liver failure, mainly due to hepatitis A (49, 93)
and E (39), although hepatitis B has also been shown to cause
acute on chronic liver failure (91). Early clinical trials in this
latter setting have shown the potential benefit of MSC therapy
(119), with a reduction in ascites volume, as well as improve-
ments in liver function and serum albumin level, although
these studies were not formal clinical trials with identified
primary end-points and, thus, need confirmation in future
studies. The mechanisms by which MSC may exert their
beneficial effects in this setting are also not clear and requires
study (94). Of note, hepatitis B virus is able to infect MSC,
although the implications of this are not entirely clear (58).
Ischemia Reperfusion and Transplantation
Ischemic liver injury is an underrecognized clinical condi-
tion occurring at its most dramatic during the ischemia-reper-
fusion injury accompanying liver transplantation (54), as well
as during episodes of hypoperfusion, such as cardiac arrest,
Table 2. Factors Secreted By MSC Known To Be Important in Immunomodulation
Cytokine Effect
Nerve growth factor (NGF) Binds to P75 on hepatic stellate cells and triggers apoptosis
Interleukin 6 (Il-6) Inhibits neutrophil burst
Inducible nitric oxide synthetase (iNOS) Inhibits CD4 T-cell function
Indolamine 2,3 dioxygenase (IDO) Inhibits CD4 T-cell function, inhibits resting natural killer cells
Prostaglandin E2 (PGE2) Inhibits CD4 T-cell function, inhibits resting natural killer cells, inhibits differentiation of monocytes
into myeloid cells, inhibits TNF production by dendritic cells
Hepatocyte growth factor (HGF) Inhibits CD4 T-cell function, inhibits CD8 T-cell cytotoxicity
Transforming growth factor  (TGF-) Inhibits CD4 T-cell function
Human leucocyte antigen G5 (HLA-G5) Inhibits resting natural killer cells
CD4+ T Lymphocyte CD8+ T Lymphocyte
NK Cell
γδ T Cell
MSC
Dendritic Cell
Monocyte
Neutrophil
FoxP3+ T Reg
IDO, iNOS, HO1,
TGFβ, HGF, PGE2 PGE2
PGE2
PGE2
IL-6
HLA-G5
HLA-G5
Fig. 1. Immune cells influenced by mesen-
chymal stem cells (MSC). MSC exert an
effect on a range of cells involved in the
immune response. There is a direct effect
exerted on CD4, CD8, T-Cells, FoxP3
T-reg cells, neutrophils, and monocytes, while
they also exert an indirect effect on natural
killer (NK) cells via their action on dendritic
cells. (Stock images provided by Servier med-
ical for use under the Creative Commons At-
tribution 3.0 Unported License).
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trauma, and sepsis (14). Recruitment of CD4 and CD8 T
cells coupled with natural killer (NK) and T cells occurs
early in ischemia reperfusion (IR) injury and is a key patho-
genic mechanism in the development of the immunity-medi-
ated liver injury (105) seen in this setting. In preclinical
studies, inhibition of leukocyte adhesion significantly reduces
liver injury in the setting of transplant-induced ischemia-
reperfusion injury (100). Hence, MSC, which have a potent
ability to suppress T-cell activity and proliferation, have been
proposed as therapeutic adjuncts in this setting (Fig. 2).
Hepatocyte transplantation has been carried out in both acute
liver failure (96) and inborn errors of metabolism (21), with
mixed results. Failure of sufficient engraftment and rejection of
transplanted hepatocytes restrict the clinical utility of this
approach, and thus, an adjunctive role of MSC has been
proposed. Notably, MSC have been shown to prolong hepato-
cyte survival both in vitro and in vivo, as well as maintain their
function (45, 104). MSC can also downregulate the number of
TUNEL-positive hepatocytes in partial hepatic injury models,
as well as increasing the number of proliferating hepatocytes
(104), and, thus, may prolong hepatocyte retention after trans-
plantation. MSC have also been shown in vitro to differentiate
into hepatocytes (6, 70) and/or fuse with hepatocytes adopting
their phenotype (101). While initially thought to be a mecha-
nism by which MSC are able to support tissue repair and
regeneration, the low numbers of such cells suggests that this
function of MSC is not the most important feature, with
inhibition of apoptosis a more likely explanation.
In preclinical studies of reduced-size liver transplantation,
MSC have been show to provide trophic support for donor livers
and improve recipient survival, although the exact mechanisms
were not studied (23). Notably, infusions of MSC that had been
transfected with an HGF adenovirus vector to stimulate their
production of HGF have been shown to further improve survival
in the setting of small for-size liver transplantation, although the
relative contributions of HGF and/or MSC in this setting require
further study (115, 116). MSC have also been shown to signifi-
cantly reduce AST and ALT, as well as decrease the number of
apoptotic hepatocytes, as assessed by the TUNEL assay in a
model of hepatic IR (48). As the MSC in this study adhered to the
peri-portal region and appeared to have reduced the number of
apoptotic hepatocytes, it seems likely that a paracrine effect is
responsible for this, and reductions in TNF- and phospho-JNK
by MSC are possible mechanisms.
Tolerogenic properties of MSC have been investigated in a
rat model of liver transplantation. Following orthotopic liver
transplantation, MSC infusion has been shown to increase
tolerance to donor organs by suppressing T-cell levels, as well
as increasing the number of circulating CD4CD25FoxP3
regulatory T cells (108, 111). Clinical translation of this effect
has yet to be demonstrated; however, although studies in
kidney transplantation look encouraging (76, 83, 97). Neutro-
phils are a key component of the inflammatory insult seen
following ischemia-reperfusion injury. MSC have been shown
to exert an effect on neutrophils. With reciprocal modulation of
the mitochondrial proteins of the Bcl2 family; Bax and MCL-1,
MSC can inhibit neutrophil apoptosis, even at a low ratio
(1:500) (79). In coculture experiments, MSC have been shown
to increase the amount of phosphorylated STAT3 via secretion
of IL-6, a likely explanation for their ability to inhibit neutro-
phil apoptosis.
Chronic Liver Disease
Liver fibrosis is the common final result of most chronic
liver diseases, and while once thought of as an irreversible
Table 3. Key clinical studies in liver disease
Study Design
Number of
Patients Treated
Etiology of Liver
Failure Type of MSC
Route of
Administration
Cell
Numbers
Predefined Primary
Endpoint Outcome
Acute on Chronic Liver
Failure
Shi et al., Stem Cells
Translational
Medicine, 2012
Open labeled nonrandomized
controlled trial
24 Hepatitis B
infection
UC MSC Peripheral
intravenous
infusion
0.5 
106·kg	3·
wk	1 at
4-wk
intervals
for 3
cycles
No Improved survival at 72
wk (20.8% vs.
47.4% P 
 0.015)
Peng et al.,
Hepatology, 2011
Nonrandomized controlled
trial
57 Hepatitis B
infection
Autologous
BM MSC
Hepatic artery
infusion
3.8  108 by
single
injection
No Improvement in MELD
score at 36 wk
(15.55 vs. 18.79)
Fibrosis/Cirrhosis
Zhang et al., Journal
of Gastroenterology
and Hepatology,
2012
Open labeled nonrandomized
controlled trial
30 Chronic Hepatitis
B infection
UC MSC Peripheral
intravenous
infusion
0.5  106/kg
every 4
wk on 3
occasions
No Improvement in ascites
volume assessed by
ultrasound (5 mm vs.
22 mm at 50 wk)
and albumin levels
(32 vs. 35 P  0.05)
Salama et al., Stem
Cell Res
Therapeutics, 2014
Randomized controlled trial 20 Hepatitis C
infection
Autologous
BM MSC
Peripheral
intravenous
infusion
1.0  106/kg
by single
infusion
No Global improvement in
liver function tests
6 mo (bilirubin
2.06 vs. 4.24, INR
1.52 vs. 1.84, ALT
fold 1.27 vs. 1.09)
Mohamadnejad et al.,
Liver International,
2013
Randomized controlled trial 15 Mixed Autologous
BM MSC
Peripheral
intravenous
infusion
1.20–2.95 
108 by
single
infusion
No 3 deaths in MSC
treated group. No
significant difference
in MELD score or
liver function tests
Xu et al., Journal of
Gastroenterology
and Hepatology,
2014
Randomized controlled trial 20 Hepatitis B
infection
Autologous
BM MSC
Hepatic artery
infusion
8.45  108
by single
infusion
No Improvement in MELD
score (11 vs. 9) and
ALT (30 vs. 25) at
24 wk
MSC, mesenchymal stem cells; UC, umbilical cord; BM, bone marrrow; MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase.
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phenomenon, there is optimism that it may be amenable to
specific antifibrotic therapies (29). Cirrhosis, the most severe
manifestation of liver fibrosis, represents the consequence of
stellate cell activation following chronic liver injury and the
deposition of extracellular matrix (ECM) proteins and collagen
(30). Fibrosis can coexist with ongoing inflammatory injury
and, thus, MSC have been explored as both anti-inflammatory
and antifibrotic therapies in this setting. Activation of stellate
cells contributes to fibrogenesis, and MSC-induced initiation of
stellate cell apoptosis has been suggested as a potential treat-
ment for hepatic fibrosis (72) (Fig. 3).
In preclinical trials, MSC have been shown to improve liver
function in models of cirrhosis and decrease expression of
-SMA, TGF-1, and type 1 collagen (47). Activated stellate
cells express the receptor P75, which triggers apoptosis in
response to nerve growth factor (NGF) probably by induction
of the C-Jun N-terminal kinase and NF-B pathways. MSC
may increase stellate cell apoptosis via the release of NGF
(57). Matrix metalloproteinase 9 (MMP9) is a protease known
to break down the ECM, and MSC have been shown to
increase the expression of MMP9, along the fibrous septa in
mouse models, leading to regression of fibrosis (37). As an
explanation for their regenerative effect in liver fibrosis, it has
been proposed that bone marrow-derived stem cells may mi-
grate to injured liver and differentiate into hepatocytes (70);
however, alternative mechanisms seem more likely. A key
criticism of the preclinical work carried out using MSC in liver
fibrosis/cirrhosis is that MSC were often administered at or
during the injury period, and thus, there is uncertainty as to
whether they are having an anti-inflammatory or antifibrotic
effect. With little mechanistic insight provided by the current
preclinical work, further study focusing on the way in which
MSC may exert their effects in these models is required.
One clinical trial in patients with liver cirrhosis demon-
strated an increased liver volume in patients treated with MSC
(51); however, this was an observational study, and a subse-
quent randomized trial showed no beneficial effects of MSC
therapy in this patient group (65). A recent review of trials
CD4+ T Lymphocyte
CD8+ T Lymphocyte
MSC
γδ T Cell
Hepatocytes
IDO, HO1, TGFβ,
 PGE2
Adhere and reduce
TNFα  and phospho-JNK
Inhibit apoptosis
(HGF)
Differentiate
PGE2
HLA-G5
Fig. 2. Mechanisms of MSC action in liver
inflammation/ischemia. MSC are able to in-
hibit CD4, CD8, and  T lymphocytes using
a variety of cytokines, including LHA-G5,
IDO, HO1, TGF, and PGE2. MSC may also
differentiate into hepatocytes, although this
occurs in low numbers. Hepatocyte apoptosis
is inhibited by MSC, secreting HGF, and
finally MSC may adhere to hepatocytes and
reduce TNF- and phosphor-JNK. (Stock
images provided by Servier medical for use
under the Creative Commons Attribution 3.0
Unported License).
Sinusoidal endothelium
Stellate cell
MSC
Hepatocytes
?
TGFβ1
αSMA
MMP9NGF
Secrete ECM
p75
Fig. 3. Mechanisms of MSC action in fibrotic
liver disease. MSC can exert effects on he-
patic stellate cells by secreting nerve growth
factor (NGF), which binds to p75 expressed
on activated stellate cells. This leads to stel-
late cell apoptosis and, therefore, a reduction
in the stellate cell secreted ECM. MSC may
also secrete MMP9, which has a direct effect
of cleaving collagen in the ECM. MSC also
act via an unknown mechanism to reduce the
secretion of stellate cell SMA and TGF.
(Stock images provided by Servier medical
for use under the Creative Commons Attribu-
tion 3.0 Unported License).
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using MSC in end-stage liver disease has demonstrated the
paucity of good quality trials with very few randomized con-
trolled trials in these patients (60). There is a need for good
quality open-label randomized trials to be carried out without
predefined end points to better answer the question of the
benefit of MSC in end-stage liver disease.
In clinical trials, it has also been suggested that MSC therapy
may improve liver function in patients with end-stage liver
disease due to hepatitis C virus, as supported by a downregu-
lation in fibrosis markers and proinflammatory cytokines (88),
alongside an upregulation of anti-inflammatory cytokines.
MSC have also been shown to improve liver function in
patients with cirrhosis secondary to chronic hepatitis B infec-
tion (75), with significant improvements in liver function tests
when compared with antivirals alone, possibly by increasing
the number of Treg (FoxP3) cells and decreasing the number
of Th17 (IL-17 T-helper) cells (114), hence altering the Treg/
Th17 ratio. Moreover, some studies suggest that the MSC
secretome may be as effective as MSC themselves, raising
questions about their mechanism of action and possibly negat-
ing the risk of stem cell infusion (7). Clearly there is consid-
erable further work to explore the mechanisms by which MSC
may be beneficial in fibrotic liver disease with immunity-
mediated interactions being the key focus of investigation.
Delivery of Cellular Therapy and Engraftment at Target
Sites
A number of routes of administration have been proposed
for the delivery of MSC in liver disease. While the classic
routes of intravenous infusion or subcutaneous injection are
more familiar, other routes such as intra-arterial and intraperi-
toneal injection, either via ultrasound guidance or at time of
surgery have also been investigated (50). The proposed advan-
tage of the intraperitoneal route over other routes in liver
disease is the ability to circumvent the lungs, an area in which
a large proportion of intravenous MSC will ultimately accu-
mulate (8). Choice of route will also be determined by a
balance between what is clinically practical, hence, the pref-
erence for systemic administration.
Homing and engraftment are important concepts when con-
sidering delivery of MSC to specific target organs such as the
liver. We have demonstrated that MSC use CD29 and CD44 to
mediate adhesion to sinusoidal endothelium in the CCl4 mouse
model of liver injury, thus increasing engraftment (4). Al-
though human MSC have also been shown to express CCR7,
CCR9, CXCR4, CXCR5, and CXCR6 (38), receptors that are
involved in homeostatic leukocyte tracking, it remains unclear
whether these are important in homing to injured tissue. Stim-
ulating MSC to upregulate receptors used for engraftment may
be one strategy to increase and target MSC homing. MSC
cultured under standard conditions quickly lose CXCR4
expression; however, when cultured under hypoxic condi-
tions CXCR4 expression is increased and may aid homing to
tissues expressing SDF-1, such as bone marrow and isch-
emic tissues (41). Cytokine stimulation in hematopoietic
stem cells has been shown to increase expression of recep-
tors responsible for engraftment and may represent another
potential strategy in MSC therapy.
While the importance of homing/engraftment of MSC to the
injured liver is assumed to be necessary, recent work in liver
fibrosis and other clinical settings such as graft vs. host disease
has questioned this premise. Encapsulated MSC (eMSC) dem-
onstrated a superior effect when compared with intravenously
administered MSC, which may be a reflection of prolonged
survival of the eMSC in vivo (117). This work suggests that
MSC may exert their effects through paracrine signaling or cell
contact with circulating inflammatory cells, such as myeloid
derived stromal or dendritic cells (18).
Techniques enabling the tracking of MSC will be important
so as to better understand their in vivo action. One early
technique for tracking cell distribution was magnetic reso-
nance imaging (MRI), of supermagnetic iron oxide (SPIO)-
labeled cells (107). There is evidence, however, that the
labeling process itself, magnetoporation, can inhibit MSC
differentiation and migration, limiting the usefulness of this
technology (90). One alternative to SPIOs are manganese
oxide nanoparticles, which have been used to track MSC in
mouse models of glioblastoma (40). Radionucleotide re-
porter gene imaging using single photon emission computed
tomography is a potential alternative to MRI; however, it is
limited by the spillover of radiation to nonlabeled cell types
and the short time frame with which imaging is possible
because of radionucleotide decay (43).
Clinical Translation of MSC Therapy
Although MSC have potentially broad-reaching clinical ap-
plications in liver disease they have yet to demonstrate un-
equivocal evidence of efficacy. This predominantly reflects the
lack of robust phase 2/3 clinical trials performed with the rigor
required by regulators to meet predefined primary end-points.
As a rare population of cells, MSC requires extensive culture
expansion to yield enough cell numbers for a clinical effect,
which raises concern about loss of function (31) and potentially
transformation. Undeniably overexpansion of MSC in culture
reduces their ability to immunosuppress subsequently, and,
thus, regimens defining maximal expansion before use are
required, along with robust release assays, which are predictive
of in vivo functionality. Concerns about transformation of
MSC in culture pertain only to murine studies (3), whereas
human studies do not suggest any evidence of transformation.
Indeed, initial evidence of oncogenesis was retracted, as it was
later shown to be due to cell line contamination (32). Longer-
term studies of patients receiving human MSC also demon-
strated the lack of any long-term engraftment, providing fur-
ther reassurance on this matter (106).
Of note, MSC require exposure to inflammation to induce
their immunomodulatory actions, whereas in a quiescent envi-
ronment, they may adopt a proinflammatory phenotype (5,
112). The desire, therefore, to prime MSC to enhance their
function poses a dilemma between additional logistical and
financial challenges at the expense of potentially greater effi-
cacy.
Inflammatory bowel disease is another group of conditions
caused by immune dysregulation in which MSC may have
potential benefit; however, so far, only small case series have
been performed. One study has demonstrated an improvement
in mucosal inflammation (56), and another study demonstrated
improvement in half of the patients and deterioration in the
others (24) following administration of MSC.
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Tumorigenicity. Tumor promotion has been considered as a
potential risk with MSC therapy, as theoretically immunosup-
pression could serve to encourage tumor initiation, and MSC
secrete angiogenic factors such as VEGF and PDGF which
may serve to promote tumor growth (10). The possibility that
MSC can give rise to tumor-associated fibroblasts has also
been considered in the literature (64), although MSC therapy in
the setting of hepatocellular carcinoma has been shown to both
inhibit tumor growth via downregulation of Wnt signaling
pathway associated factors, while promoting tumor growth by
secretion of trophic factors in other models (36). The hetero-
geneity in the literature is possibly a reflection of transforma-
tion of MSC, which is found more commonly in the murine
setting, especially after isolation using plastic adherence tech-
niques (52).
Two reports of spontaneous transformation of human MSC
upon transplantation (85, 86) led to the suspension of several
human plastic adherent (PA)-MSC clinical trials, although both
reports (85, 86) were subsequently retracted, as rigorous anal-
ysis revealed that the PA-MSC used in both studies was
cross-contaminated by the human HT1080 fibrosarcoma cancer
cell line (20, 102). To date, only one report has ever demon-
strated that human adult tissue-derived PA-MSC can sponta-
neously transform. Wang et al. (110) generated PA-MSC lines
from over 100 donors, and of these lines, one donor PA-MSC
line formed tumors in nonobese diabetic severe combined
immunodeficiency (NOD/SCID) immunity-compromised mice
(110). This cell displayed an abnormal (non-International So-
ciety for Cellular Therapy) cell surface cytometry profile of
CD133, CD90low, CD105	, VEGFR2, whereas normal PA-
MSC express high levels of CD90 and CD105, but do not
express CD133 or VEGFR2 in culture. Karyotyping showed
chromosome aneuploidy, and these cells expressed a high level
of telomerase activity, compared with typical PA-MSC. As a
result of this study, every clinical grade batch of PA-MSC
currently undergoes karyotyping and flow cytometry as batch
release criteria.
More robust data using rodent PA-MSC have raised con-
cerns that the use of rodent MSC can lead to cancer in certain
rodent models either directly or through promotion of existing
early stage cancer. Miura et al. (64a) showed that murine MSC
could bypass senescence and passage 65 MSC injected into
mice formed fibrosarcomas in multiple organs. Raising addi-
tional concerns, Breitbach et al. (15) reported that murine
PA-MSC led to ectopic bone formation in infarcted mouse
hearts. Foudah et al. (25) report that rat MSC (rMSC) exhibited
genomic instability and tumorigenicity in culture, leading to
the conclusion that rat MSC may not be a good model for
exploring the therapeutic potential of human MSC. Jeong et al.
(42) extended these findings, showing that murine MSC exhibit
genetic instabilities at low passages and lead to tumors in the
heart and hindlimbs of mice. Chromosomal analysis revealed
that culturing these normal-looking, tumorigenic mouse PA-
MSC cause multiple chromosomal abnormalities. These re-
ports must be taken seriously, however, as the increased
susceptibility of inbred rodent cells to transformation is well
described, these findings may not be surprising, and when
considering human cells, it should be noted that they are
reportedly resistant to oncogenesis. The Weinberg lab has
described that tumorigenic transformation of normal human
fibroblasts requires the mutation of six different signaling
pathways, whereas mouse fibroblasts require only two pathway
mutations (p53 and Raf) to bypass senescence and transform
(81).
Nonetheless, careful monitoring for adverse effects of PA-
MSC therapies in nonclinical and clinical settings continues to
support an acceptable safety profile for PA-MSC with regard to
proliferation or ectopic tissue formation. Finally, recent au-
topsy data from GvHD clinical trial patients that received
PA-MSC between 2002 and 2007, revealed no ectopic tissue,
neoplasms, or donor-derived DNA (106).
Conclusions. MSC have been shown to reduce immunity-
mediated liver injury, oxidative stress, and stimulate liver
regeneration in a range of preclinical models, but there still
remains a lack of detailed studies delineating the mechanisms
by which MSC achieve their effects. While the clinical trans-
lation of these effects is yet to be confirmed in large-scale
randomized trials, there are an increasing number of such
studies under way. These studies will hopefully shed light on
which clinical indications are appropriate, as well as provide
added insights on dosing regimen and safety profile.
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